Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2021

Open Access 01-12-2021 | Heart Failure | Research

Prognostic relevance of elevated plasma osmolality on admission in acute decompensated heart failure with preserved ejection fraction: insights from PURSUIT-HFpEF registry

Authors: Akito Nakagawa, Yoshio Yasumura, Chikako Yoshida, Takahiro Okumura, Jun Tateishi, Junichi Yoshida, Shunsuke Tamaki, Masamichi Yano, Takaharu Hayashi, Yusuke Nakagawa, Takahisa Yamada, Daisaku Nakatani, Shungo Hikoso, Yasushi Sakata, Osaka CardioVascular Conference (OCVC) Heart Failure Investigators

Published in: BMC Cardiovascular Disorders | Issue 1/2021

Login to get access

Abstract

Background

Complicated pathophysiology makes it difficult to identify the prognosis of heart failure with preserved ejection fraction (HFpEF). While plasma osmolality has been reported to have prognostic importance, mainly in heart failure with reduced ejection fraction (HFrEF), its prognostic meaning for HFpEF has not been elucidated.

Methods

We prospectively studied 960 patients in PURSUIT-HFpEF, a multicenter observational study of acute decompensated HFpEF inpatients. We divided patients into three groups according to the quantile values of plasma osmolality on admission. During a follow-up averaging 366 days, we examined the primary composite endpoint of cardiac mortality or heart failure re-admission using Kaplan–Meier curve analysis and Cox proportional hazard testing.

Results

216 (22.5%) patients reached the primary endpoint. Kaplan–Meier curve analysis revealed that the highest quantile of plasma osmolality on admission (higher than 300.3 mOsm/kg) was significantly associated with adverse outcomes (Log-rank P = 0.0095). Univariable analysis in the Cox proportional hazard model also revealed significantly higher rates of adverse outcomes in the higher plasma osmolality on admission (hazard ratio [HR] 7.29; 95% confidence interval [CI] 2.25–23.92, P = 0.0009). Multivariable analysis in the Cox proportional hazard model also showed that higher plasma osmolality on admission was significantly associated with adverse outcomes (HR 5.47; 95% CI 1.46–21.56, P = 0.0113) independently from other confounding factors such as age, gender, comorbid of atrial fibrillation, hypertension history, diabetes, anemia, malnutrition, E/e′, and N-terminal pro-B-type natriuretic peptide elevation.

Conclusions

Higher plasma osmolality on admission was prognostically important for acute decompensated HFpEF inpatients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.CrossRef Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.CrossRef
2.
go back to reference Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016;375(19):1868–77.CrossRef Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016;375(19):1868–77.CrossRef
3.
go back to reference Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507–15.CrossRef Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507–15.CrossRef
4.
go back to reference Rasouli M. Basic concepts and practical equations on osmolality: biochemical approach. Clin Biochem. 2016;49(12):936–41.CrossRef Rasouli M. Basic concepts and practical equations on osmolality: biochemical approach. Clin Biochem. 2016;49(12):936–41.CrossRef
5.
go back to reference Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O’Connor CM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28(8):980–8.CrossRef Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O’Connor CM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28(8):980–8.CrossRef
6.
go back to reference Jujo K, Minami Y, Haruki S, Matsue Y, Shimazaki K, Kadowaki H, et al. Persistent high blood urea nitrogen level is associated with increased risk of cardiovascular events in patients with acute heart failure. ESC Heart Failure. 2017;4(4):545–53.CrossRef Jujo K, Minami Y, Haruki S, Matsue Y, Shimazaki K, Kadowaki H, et al. Persistent high blood urea nitrogen level is associated with increased risk of cardiovascular events in patients with acute heart failure. ESC Heart Failure. 2017;4(4):545–53.CrossRef
7.
go back to reference Mebazaa A, Gayat E, Lassus J, Meas T, Mueller C, Maggioni A, et al. Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol. 2013;61(8):820–9.CrossRef Mebazaa A, Gayat E, Lassus J, Meas T, Mueller C, Maggioni A, et al. Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol. 2013;61(8):820–9.CrossRef
8.
go back to reference Prenner SB, Pillutla R, Yenigalla S, Gaddam S, Lee J, Obeid MJ, et al. Serum albumin is a marker of myocardial fibrosis, adverse pulsatile aortic hemodynamics, and prognosis in heart failure with preserved ejection fraction. J Am Heart Assoc. 2020;9(3):e014716.CrossRef Prenner SB, Pillutla R, Yenigalla S, Gaddam S, Lee J, Obeid MJ, et al. Serum albumin is a marker of myocardial fibrosis, adverse pulsatile aortic hemodynamics, and prognosis in heart failure with preserved ejection fraction. J Am Heart Assoc. 2020;9(3):e014716.CrossRef
9.
go back to reference Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10):1987–96.CrossRef Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10):1987–96.CrossRef
10.
go back to reference Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol. 2005;95(9a):8b–13b.CrossRef Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol. 2005;95(9a):8b–13b.CrossRef
11.
go back to reference Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int. 1976;10(1):25–37.CrossRef Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int. 1976;10(1):25–37.CrossRef
12.
go back to reference Riegger AJ, Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. Clin Sci (London, England 1979). 1982;62(5):465–9.CrossRef Riegger AJ, Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. Clin Sci (London, England 1979). 1982;62(5):465–9.CrossRef
13.
go back to reference Vaduganathan M, Marti CN, Mentz RJ, Greene SJ, Ambrosy AP, Subacius HP, et al. Serum osmolality and postdischarge outcomes after hospitalization for heart failure. Am J Cardiol. 2016;117(7):1144–50.CrossRef Vaduganathan M, Marti CN, Mentz RJ, Greene SJ, Ambrosy AP, Subacius HP, et al. Serum osmolality and postdischarge outcomes after hospitalization for heart failure. Am J Cardiol. 2016;117(7):1144–50.CrossRef
14.
go back to reference Kaya H, Yucel O, Ege MR, Zorlu A, Yucel H, Gunes H, et al. Plasma osmolality predicts mortality in patients with heart failure with reduced ejection fraction. Kardiol Pol. 2017;75(4):316–22.CrossRef Kaya H, Yucel O, Ege MR, Zorlu A, Yucel H, Gunes H, et al. Plasma osmolality predicts mortality in patients with heart failure with reduced ejection fraction. Kardiol Pol. 2017;75(4):316–22.CrossRef
15.
go back to reference Arevalo-Lorido JC, Gomez JC, Formiga F, Conde-Martel A, Carrera-Izquierdo M, Muela-Molinero A, et al. High serum osmolarity at admission determines a worse outcome in patients with heart failure: Is a new target emerging? Int J Cardiol. 2016;221:238–42.CrossRef Arevalo-Lorido JC, Gomez JC, Formiga F, Conde-Martel A, Carrera-Izquierdo M, Muela-Molinero A, et al. High serum osmolarity at admission determines a worse outcome in patients with heart failure: Is a new target emerging? Int J Cardiol. 2016;221:238–42.CrossRef
16.
go back to reference Suna S, Hikoso S, Yamada T, Uematsu M, Yasumura Y, Nakagawa A, et al. Study protocol for the PURSUIT-HFpEF study: a prospective, multicenter, observational study of patients with heart failure with preserved ejection fraction. BMJ Open. 2020;10(10):e038294.CrossRef Suna S, Hikoso S, Yamada T, Uematsu M, Yasumura Y, Nakagawa A, et al. Study protocol for the PURSUIT-HFpEF study: a prospective, multicenter, observational study of patients with heart failure with preserved ejection fraction. BMJ Open. 2020;10(10):e038294.CrossRef
17.
go back to reference Matsumura Y, Hattori A, Manabe S, Takahashi D, Yamamoto Y, Murata T, et al. Case report form reporter: a key component for the integration of electronic medical records and the electronic data capture system. Stud Health Technol Inform. 2017;245:516–20.PubMed Matsumura Y, Hattori A, Manabe S, Takahashi D, Yamamoto Y, Murata T, et al. Case report form reporter: a key component for the integration of electronic medical records and the electronic data capture system. Stud Health Technol Inform. 2017;245:516–20.PubMed
18.
go back to reference Kinugasa Y, Kato M, Sugihara S, Hirai M, Yamada K, Yanagihara K, et al. Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J. 2013;77(3):705–11.CrossRef Kinugasa Y, Kato M, Sugihara S, Hirai M, Yamada K, Yanagihara K, et al. Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J. 2013;77(3):705–11.CrossRef
19.
go back to reference Ling HZ, Flint J, Damgaard M, Bonfils PK, Cheng AS, Aggarwal S, et al. Calculated plasma volume status and prognosis in chronic heart failure. Eur J Heart Fail. 2015;17(1):35–43.CrossRef Ling HZ, Flint J, Damgaard M, Bonfils PK, Cheng AS, Aggarwal S, et al. Calculated plasma volume status and prognosis in chronic heart failure. Eur J Heart Fail. 2015;17(1):35–43.CrossRef
20.
go back to reference Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14.CrossRef Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14.CrossRef
21.
go back to reference Fazekas AS, Funk GC, Klobassa DS, Ruther H, Ziegler I, Zander R, et al. Evaluation of 36 formulas for calculating plasma osmolality. Intensive Care Med. 2013;39(2):302–8.CrossRef Fazekas AS, Funk GC, Klobassa DS, Ruther H, Ziegler I, Zander R, et al. Evaluation of 36 formulas for calculating plasma osmolality. Intensive Care Med. 2013;39(2):302–8.CrossRef
22.
go back to reference Rusinaru D, Tribouilloy C, Berry C, Richards AM, Whalley GA, Earle N, et al. Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis(dagger): Meta-Analysis Global Group in Chronic heart failure (MAGGIC). Eur J Heart Fail. 2012;14(10):1139–46.CrossRef Rusinaru D, Tribouilloy C, Berry C, Richards AM, Whalley GA, Earle N, et al. Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis(dagger): Meta-Analysis Global Group in Chronic heart failure (MAGGIC). Eur J Heart Fail. 2012;14(10):1139–46.CrossRef
23.
go back to reference Bie P, Damkjaer M. Renin secretion and total body sodium: pathways of integrative control. Clin Exp Pharmacol Physiol. 2010;37(2):e34-42.CrossRef Bie P, Damkjaer M. Renin secretion and total body sodium: pathways of integrative control. Clin Exp Pharmacol Physiol. 2010;37(2):e34-42.CrossRef
24.
go back to reference Oren RM. Hyponatremia in congestive heart failure. Am J Cardiol. 2005;95(9a):2b–7b.CrossRef Oren RM. Hyponatremia in congestive heart failure. Am J Cardiol. 2005;95(9a):2b–7b.CrossRef
25.
go back to reference Rowe JW, Minaker KL, Sparrow D, Robertson GL. Age-related failure of volume-pressure-mediated vasopressin release. J Clin Endocrinol Metab. 1982;54(3):661–4.CrossRef Rowe JW, Minaker KL, Sparrow D, Robertson GL. Age-related failure of volume-pressure-mediated vasopressin release. J Clin Endocrinol Metab. 1982;54(3):661–4.CrossRef
26.
go back to reference Boorsma EM, Ter Maaten JM, Damman K, Dinh W, Gustafsson F, Goldsmith S, et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol. 2020;17(10):641–55.CrossRef Boorsma EM, Ter Maaten JM, Damman K, Dinh W, Gustafsson F, Goldsmith S, et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol. 2020;17(10):641–55.CrossRef
27.
go back to reference Christ-Crain M, Fenske W. Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis. Nat Rev Endocrinol. 2016;12(3):168–76.CrossRef Christ-Crain M, Fenske W. Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis. Nat Rev Endocrinol. 2016;12(3):168–76.CrossRef
28.
go back to reference Schurtz G, Lamblin N, Bauters C, Goldstein P, Lemesle G. Copeptin in acute coronary syndromes and heart failure management: state of the art and future directions. Arch Cardiovasc Dis. 2015;108(6–7):398–407.CrossRef Schurtz G, Lamblin N, Bauters C, Goldstein P, Lemesle G. Copeptin in acute coronary syndromes and heart failure management: state of the art and future directions. Arch Cardiovasc Dis. 2015;108(6–7):398–407.CrossRef
29.
go back to reference Zhong Y, Wang R, Yan L, Lin M, Liu X, You T. Copeptin in heart failure: review and meta-analysis. Clinica Chimica Acta Int J Clin Chem. 2017;475:36–43.CrossRef Zhong Y, Wang R, Yan L, Lin M, Liu X, You T. Copeptin in heart failure: review and meta-analysis. Clinica Chimica Acta Int J Clin Chem. 2017;475:36–43.CrossRef
30.
go back to reference Hage C, Lund LH, Donal E, Daubert JC, Linde C, Mellbin L. Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study. Open Heart. 2015;2(1):e000260.CrossRef Hage C, Lund LH, Donal E, Daubert JC, Linde C, Mellbin L. Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study. Open Heart. 2015;2(1):e000260.CrossRef
31.
go back to reference Omote K, Nagai T, Kamiya K, Aikawa T, Tsujinaga S, Kato Y, et al. Long-term prognostic significance of admission tricuspid regurgitation pressure gradient in hospitalized patients with heart failure with preserved ejection fraction: a report from the Japanese Real-World Multicenter Registry. J Cardiac Fail. 2019;25(12):978–85.CrossRef Omote K, Nagai T, Kamiya K, Aikawa T, Tsujinaga S, Kato Y, et al. Long-term prognostic significance of admission tricuspid regurgitation pressure gradient in hospitalized patients with heart failure with preserved ejection fraction: a report from the Japanese Real-World Multicenter Registry. J Cardiac Fail. 2019;25(12):978–85.CrossRef
32.
go back to reference Palazzuoli A, Ruocco G, Beltrami M, Nuti R, Cleland JG. Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF. Clin Res Cardiol. 2018;107(7):586–96.CrossRef Palazzuoli A, Ruocco G, Beltrami M, Nuti R, Cleland JG. Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF. Clin Res Cardiol. 2018;107(7):586–96.CrossRef
33.
go back to reference Huang A, Qi X, Hou W, Qi Y, Zhao N, Liu K. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction. Acta Cardiol. 2018;73(1):41–8.CrossRef Huang A, Qi X, Hou W, Qi Y, Zhao N, Liu K. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction. Acta Cardiol. 2018;73(1):41–8.CrossRef
34.
go back to reference Carrasco-Sanchez FJ, Galisteo-Almeda L, Paez-Rubio I, Martinez-Marcos FJ, Camacho-Vazquez C, Ruiz-Frutos C, et al. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Cardiac Fail. 2011;17(1):31–8.CrossRef Carrasco-Sanchez FJ, Galisteo-Almeda L, Paez-Rubio I, Martinez-Marcos FJ, Camacho-Vazquez C, Ruiz-Frutos C, et al. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Cardiac Fail. 2011;17(1):31–8.CrossRef
35.
go back to reference Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.CrossRef Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.CrossRef
36.
go back to reference McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (London, England). 2003;362(9386):767–71.CrossRef McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (London, England). 2003;362(9386):767–71.CrossRef
37.
go back to reference McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.CrossRef McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.CrossRef
38.
go back to reference Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.CrossRef Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.CrossRef
39.
go back to reference Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20.CrossRef Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20.CrossRef
40.
go back to reference Fazekas AS, Funk GC, Klobassa DS, Rüther H, Ziegler I, Zander R, et al. Evaluation of 36 formulas for calculating plasma osmolality. Intensive Care Med. 2013;39(2):302–8.CrossRef Fazekas AS, Funk GC, Klobassa DS, Rüther H, Ziegler I, Zander R, et al. Evaluation of 36 formulas for calculating plasma osmolality. Intensive Care Med. 2013;39(2):302–8.CrossRef
Metadata
Title
Prognostic relevance of elevated plasma osmolality on admission in acute decompensated heart failure with preserved ejection fraction: insights from PURSUIT-HFpEF registry
Authors
Akito Nakagawa
Yoshio Yasumura
Chikako Yoshida
Takahiro Okumura
Jun Tateishi
Junichi Yoshida
Shunsuke Tamaki
Masamichi Yano
Takaharu Hayashi
Yusuke Nakagawa
Takahisa Yamada
Daisaku Nakatani
Shungo Hikoso
Yasushi Sakata
Osaka CardioVascular Conference (OCVC) Heart Failure Investigators
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
Heart Failure
Published in
BMC Cardiovascular Disorders / Issue 1/2021
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-021-02098-z

Other articles of this Issue 1/2021

BMC Cardiovascular Disorders 1/2021 Go to the issue